Revista médica de Chile
-
Revista médica de Chile · Nov 2020
Case ReportsTrametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case.
MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d) after using interferon without benefit. Shortly after starting trametinib/dabrafenib, she experienced an inability to abduct the left eye. ⋯ She could not eat or drink during four days prior to admission. The patient suspected an adverse effect of trametinib/dabrafenib and discontinued it 2 days prior to admission. Thereafter, she experienced an almost complete remission of the deficits except for ocular muscle weakness and visual impairment.
-
Revista médica de Chile · Nov 2020
[Adherence to COVID-19 trasmission prevention measures among health care workers].
COVID-19 is highly transmissible, thus requiring strict measures to prevent its propagation. ⋯ The adherence reported by health care workers was adequate in most of the evaluated recommendations.
-
Revista médica de Chile · Nov 2020
[Prevalence of low hand grip strength in Chilean older adults. Findings from the national health survey 2016-2017].
Handgrip strength is an indicator of frailty in older people. ⋯ The prevalence of low grip strength increased substantially with age.
-
The prognosis of Non-Hodgkin Lymphoma (NHL) depends on the type of lymphoma, the extension of the disease and the response to therapy. ⋯ Early treatment response assessed by interim PET/CT is the strongest prognostic factor in NHL patients.
-
Revista médica de Chile · Nov 2020
[Analysis of the organ allocation system for liver transplantation in Chile].
In Chile, organ allocation for liver transplantation (LT) in adults is prioritized according to the MELD-Na score. Exceptions such as Hepatocellular Carcinoma (HCC) and other non-HCC exceptions receive a score called Operational MELD score. ⋯ MELD-Na score can discriminate very well patients who have a higher risk of death in the short and medium term. However, the assignment of operational scores for situations of exception produces inequities in the allocation of organs for LT and must therefore be carefully adjusted.